Share Price and Basic Stock Data
Last Updated: December 12, 2025, 8:11 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gayatri BioOrganics Ltd operates in the niche sector of organic chemicals, specifically cellulose derivatives. The company’s recent performance has been notably challenging. In the financial year ending March 2023, Gayatri reported a meager revenue of ₹1.67 lakh, a stark contrast to the ₹213.97 Cr recorded back in March 2014. This decline indicates a significant contraction in business operations, especially considering that the company has struggled to generate consistent sales in the subsequent quarters, with zero revenue reported from June 2022 through September 2023. The lack of a robust revenue stream raises concerns about the company’s operational viability and market positioning. Investors looking at Gayatri should be aware of this troubling trend, as it may affect the company’s ability to reinvest in future growth or service existing debt obligations.
Profitability and Efficiency Metrics
Profitability metrics for Gayatri BioOrganics are equally concerning. The company has consistently posted net losses over the years, culminating in a net loss of ₹0.77 Cr for FY 2023. The operating profit margin (OPM) stood at a staggering -46.11%, highlighting the inefficiencies in cost management and operational execution. Moreover, the interest coverage ratio (ICR) of -1.62 suggests that the company is not generating enough income to cover its interest expenses, which is a red flag for any potential investor. The company’s return on capital employed (ROCE) fell to -54.61%, indicating that the capital invested in the business is not yielding positive returns. These figures reflect a business struggling to maintain profitability, which is critical for long-term sustainability.
Balance Sheet Strength and Financial Ratios
A close examination of Gayatri’s balance sheet reveals a complicated financial position. The company has reported negative reserves of ₹115.16 Cr, which raises concerns about its solvency and overall financial health. Borrowings are relatively high at ₹37.29 Cr, yet the company’s current ratio is alarmingly low at 0.04, indicating inadequate liquidity to meet short-term obligations. This precarious balance sheet situation is compounded by the negative book value per share of ₹4.55, suggesting that shareholders may be at risk if the company does not turn around its fortunes. The financial ratios reflect a company heavily burdened by debt and struggling to maintain a stable financial footing, making it a risky investment proposition.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Gayatri BioOrganics presents a mixed picture. As of March 2025, promoters hold 21.59% of the shares, a significant drop from 40.63% in the previous year. This reduction could signal a lack of confidence in the company’s future prospects among its founders. Institutional ownership remains minimal, with foreign institutional investors (FIIs) at just 0.01% and domestic institutional investors (DIIs) at 0.65%. Public ownership has surged to 77.77%, indicating that retail investors are now the primary stakeholders. This could suggest either a growing interest from individual investors or a lack of institutional faith in the company’s recovery, adding another layer of risk to the investment narrative.
Outlook, Risks, and Final Insight
Looking ahead, the outlook for Gayatri BioOrganics appears fraught with challenges. The absence of consistent revenue generation and ongoing financial losses present significant hurdles. Investors should be cautious of the high debt load, low liquidity, and negative profitability, which could threaten the company’s long-term viability. Furthermore, the recent decline in promoter shareholding raises questions about insider confidence, which is often a crucial indicator of a company’s future direction. While there may be potential for turnaround if management can effectively address operational inefficiencies and revitalize sales, the risks remain substantial. Investors should weigh these factors carefully, considering both the possibility of recovery and the inherent uncertainties surrounding the company’s future performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gayatri BioOrganics Ltd | 122 Cr. | 15.4 | 15.7/5.35 | 4.62 | 0.00 % | 40.7 % | % | 10.0 | |
| Industry Average | 122.00 Cr | 15.40 | 0 | 4.62 | 0.00% | 40.70% | 0% | 10.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 1.67 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.16 | 0.24 | 0.12 | 2.31 | 0.18 | 0.07 | 0.10 | 0.18 | 0.15 | 0.11 | 0.08 | 0.10 | 0.18 |
| Operating Profit | -0.16 | -0.24 | -0.12 | -0.64 | -0.18 | -0.07 | -0.10 | -0.18 | -0.15 | -0.11 | -0.08 | -0.10 | -0.18 |
| OPM % | -38.32% | ||||||||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 | 0.04 | 0.04 | 0.05 | 0.06 | 0.07 | 0.08 | 0.07 | 0.08 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.16 | -0.24 | -0.12 | -0.67 | -0.20 | -0.11 | -0.14 | -0.23 | -0.21 | -0.18 | -0.16 | -0.17 | -0.26 |
| Tax % | 0.00% | 87.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.16 | -0.45 | -0.12 | -0.67 | -0.20 | -0.11 | -0.14 | -0.23 | -0.21 | -0.18 | -0.16 | -0.17 | -0.26 |
| EPS in Rs | -0.02 | -0.06 | -0.02 | -0.09 | -0.03 | -0.01 | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 | -0.02 | -0.03 |
Last Updated: August 19, 2025, 2:50 pm
Below is a detailed analysis of the quarterly data for Gayatri BioOrganics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Expenses, as of Jun 2025, the value is 0.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.10 Cr. (Mar 2025) to 0.18 Cr., marking an increase of 0.08 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.18 Cr.. The value appears to be declining and may need further review. It has decreased from -0.10 Cr. (Mar 2025) to -0.18 Cr., marking a decrease of 0.08 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.08 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.07 Cr. (Mar 2025) to 0.08 Cr., marking an increase of 0.01 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -0.26 Cr.. The value appears to be declining and may need further review. It has decreased from -0.17 Cr. (Mar 2025) to -0.26 Cr., marking a decrease of 0.09 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is -0.26 Cr.. The value appears to be declining and may need further review. It has decreased from -0.17 Cr. (Mar 2025) to -0.26 Cr., marking a decrease of 0.09 Cr..
- For EPS in Rs, as of Jun 2025, the value is -0.03. The value appears to be declining and may need further review. It has decreased from -0.02 (Mar 2025) to -0.03, marking a decrease of 0.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 213.97 | 255.89 | 137.22 | 79.32 | 173.32 | 155.48 | 0.00 | 0.00 | 0.00 | 1.67 | 0.00 | 0.00 | 0.00 |
| Expenses | 201.10 | 240.58 | 162.03 | 128.53 | 197.18 | 159.09 | 0.61 | 0.50 | 0.50 | 2.44 | 0.53 | 0.45 | 0.48 |
| Operating Profit | 12.87 | 15.31 | -24.81 | -49.21 | -23.86 | -3.61 | -0.61 | -0.50 | -0.50 | -0.77 | -0.53 | -0.45 | -0.48 |
| OPM % | 6.01% | 5.98% | -18.08% | -62.04% | -13.77% | -2.32% | -46.11% | ||||||
| Other Income | 0.30 | 1.27 | 0.96 | -16.53 | 11.87 | 2.10 | 85.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 7.57 | 9.39 | 12.74 | 11.57 | 0.19 | 4.71 | 0.01 | 0.00 | 0.00 | 0.03 | 0.15 | 0.28 | 0.32 |
| Depreciation | 4.25 | 2.37 | 2.13 | 5.34 | 6.96 | 9.29 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 1.35 | 4.82 | -38.72 | -82.65 | -19.14 | -15.51 | 84.47 | -0.50 | -0.50 | -0.80 | -0.68 | -0.73 | -0.80 |
| Tax % | 0.00% | 18.26% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 26.25% | 0.00% | 0.00% | |
| Net Profit | 1.35 | 3.93 | -38.73 | -82.65 | -19.14 | -15.51 | 84.47 | -0.50 | -0.50 | -1.01 | -0.68 | -0.73 | -0.80 |
| EPS in Rs | 0.27 | 0.77 | -6.27 | -10.49 | -2.43 | -1.97 | 10.72 | -0.06 | -0.06 | -0.13 | -0.09 | -0.09 | -0.10 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 191.11% | -1085.50% | -113.40% | 76.84% | 18.97% | 644.62% | -100.59% | 0.00% | -102.00% | 32.67% | -7.35% |
| Change in YoY Net Profit Growth (%) | 0.00% | -1276.61% | 972.10% | 190.24% | -57.88% | 625.65% | -745.21% | 100.59% | -102.00% | 134.67% | -40.03% |
Gayatri BioOrganics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -8% |
| 3 Years: | -19% |
| TTM: | -12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 18% |
| 3 Years: | 3% |
| 1 Year: | 103% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Last Updated: September 5, 2025, 3:31 pm
Balance Sheet
Last Updated: December 4, 2025, 2:56 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 50.92 | 50.92 | 61.78 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 | 78.79 |
| Reserves | -44.79 | -40.86 | -79.58 | -159.93 | -181.20 | -195.74 | -111.27 | -111.77 | -112.26 | -113.27 | -113.95 | -114.68 | -115.16 |
| Borrowings | 75.47 | 88.12 | 115.50 | 35.11 | 35.11 | 35.11 | 35.11 | 35.11 | 35.11 | 35.66 | 36.36 | 36.90 | 37.29 |
| Other Liabilities | 94.72 | 43.94 | 44.00 | 150.81 | 212.77 | 226.93 | 0.46 | 0.47 | 0.60 | 0.44 | 0.37 | 0.66 | 0.75 |
| Total Liabilities | 176.32 | 142.12 | 141.70 | 104.78 | 145.47 | 145.09 | 3.09 | 2.60 | 2.24 | 1.62 | 1.57 | 1.67 | 1.67 |
| Fixed Assets | 48.88 | 47.19 | 45.69 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.37 | 5.80 | 6.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 127.07 | 89.13 | 90.00 | 104.78 | 145.47 | 145.09 | 3.09 | 2.60 | 2.24 | 1.62 | 1.57 | 1.67 | 1.67 |
| Total Assets | 176.32 | 142.12 | 141.70 | 104.78 | 145.47 | 145.09 | 3.09 | 2.60 | 2.24 | 1.62 | 1.57 | 1.67 | 1.67 |
Below is a detailed analysis of the balance sheet data for Gayatri BioOrganics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 78.79 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 78.79 Cr..
- For Reserves, as of Sep 2025, the value is -115.16 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -114.68 Cr. (Mar 2025) to -115.16 Cr., marking a decline of 0.48 Cr..
- For Borrowings, as of Sep 2025, the value is 37.29 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 36.90 Cr. (Mar 2025) to 37.29 Cr., marking an increase of 0.39 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.75 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.66 Cr. (Mar 2025) to 0.75 Cr., marking an increase of 0.09 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1.67 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.67 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1.67 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.67 Cr..
- For Total Assets, as of Sep 2025, the value is 1.67 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.67 Cr..
However, the Borrowings (37.29 Cr.) are higher than the Reserves (-115.16 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -62.60 | -72.81 | -140.31 | -84.32 | -58.97 | -38.72 | -35.72 | -35.61 | -35.61 | -36.43 | -36.89 | -37.35 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 162.69 | 63.12 | 116.05 | 6.95 | 3.18 | 1.22 | 54.64 | |||||
| Inventory Days | 51.08 | 62.87 | 98.30 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Days Payable | 177.53 | 58.80 | 79.17 | |||||||||
| Cash Conversion Cycle | 36.24 | 67.19 | 135.18 | 6.95 | 3.18 | 1.22 | 54.64 | |||||
| Working Capital Days | -18.12 | 5.32 | -103.13 | -365.55 | -212.09 | -271.31 | -7,048.65 | |||||
| ROCE % | 10.65% | 14.68% | -27.28% | -209.87% | -21.01% | -26.53% | -54.61% | -44.54% | -40.72% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Large & Midcap Fund | 452,200 | 0 | 0.55 | 452,200 | 2025-04-22 15:56:50 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -72.65 | -0.09 | -0.13 | -0.06 | -0.06 |
| Diluted EPS (Rs.) | -72.65 | -0.09 | -0.13 | -0.06 | -0.06 |
| Cash EPS (Rs.) | -0.09 | -0.08 | -0.12 | -0.06 | -0.06 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -4.55 | -4.46 | -4.38 | -4.25 | -4.18 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -4.55 | -4.46 | -4.38 | -4.25 | -4.18 |
| Revenue From Operations / Share (Rs.) | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 |
| PBDIT / Share (Rs.) | -0.05 | -0.06 | -0.09 | -0.06 | -0.06 |
| PBIT / Share (Rs.) | -0.05 | -0.06 | -0.09 | -0.06 | -0.06 |
| PBT / Share (Rs.) | -0.09 | -0.08 | -0.10 | -0.06 | -0.06 |
| Net Profit / Share (Rs.) | -0.09 | -0.08 | -0.12 | -0.06 | -0.06 |
| PBDIT Margin (%) | 0.00 | 0.00 | -46.06 | 0.00 | 0.00 |
| PBIT Margin (%) | 0.00 | 0.00 | -46.06 | 0.00 | 0.00 |
| PBT Margin (%) | 0.00 | 0.00 | -47.72 | 0.00 | 0.00 |
| Net Profit Margin (%) | 0.00 | 0.00 | -60.60 | 0.00 | 0.00 |
| Return on Capital Employeed (%) | 1.38 | 1.65 | 2.38 | 1.56 | 1.58 |
| Return On Assets (%) | -43.67 | -43.18 | -62.54 | -22.19 | -19.17 |
| Long Term Debt / Equity (X) | -0.09 | -0.08 | -0.06 | -0.05 | -0.05 |
| Total Debt / Equity (X) | -1.03 | -1.03 | -1.03 | -1.05 | -1.06 |
| Asset Turnover Ratio (%) | 0.00 | 0.00 | 0.86 | 0.00 | 0.00 |
| Current Ratio (X) | 0.04 | 0.04 | 0.04 | 0.06 | 0.07 |
| Quick Ratio (X) | 0.04 | 0.04 | 0.04 | 0.06 | 0.07 |
| Interest Coverage Ratio (X) | -1.62 | -3.56 | -27.83 | -1652.67 | -496.40 |
| Interest Coverage Ratio (Post Tax) (X) | -1.62 | -3.56 | -35.61 | -1652.67 | -496.40 |
| Enterprise Value (Cr.) | 90.61 | 75.80 | 92.13 | 182.80 | 85.41 |
| EV / Net Operating Revenue (X) | 0.00 | 0.00 | 55.25 | 0.00 | 0.00 |
| EV / EBITDA (X) | -201.50 | -142.51 | -119.94 | -368.70 | -172.05 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 0.00 | 33.88 | 0.00 | 0.00 |
| Price / BV (X) | -1.50 | -1.12 | -1.64 | -4.41 | -1.54 |
| Price / Net Operating Revenue (X) | 0.00 | 0.00 | 33.98 | 0.00 | 0.00 |
| EarningsYield | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 |
After reviewing the key financial ratios for Gayatri BioOrganics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -72.65. This value is below the healthy minimum of 5. It has decreased from -0.09 (Mar 24) to -72.65, marking a decrease of 72.56.
- For Diluted EPS (Rs.), as of Mar 25, the value is -72.65. This value is below the healthy minimum of 5. It has decreased from -0.09 (Mar 24) to -72.65, marking a decrease of 72.56.
- For Cash EPS (Rs.), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 3. It has decreased from -0.08 (Mar 24) to -0.09, marking a decrease of 0.01.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -4.55. It has decreased from -4.46 (Mar 24) to -4.55, marking a decrease of 0.09.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -4.55. It has decreased from -4.46 (Mar 24) to -4.55, marking a decrease of 0.09.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.05. This value is below the healthy minimum of 2. It has increased from -0.06 (Mar 24) to -0.05, marking an increase of 0.01.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.05. This value is below the healthy minimum of 0. It has increased from -0.06 (Mar 24) to -0.05, marking an increase of 0.01.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 0. It has decreased from -0.08 (Mar 24) to -0.09, marking a decrease of 0.01.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 2. It has decreased from -0.08 (Mar 24) to -0.09, marking a decrease of 0.01.
- For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Net Profit Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Capital Employeed (%), as of Mar 25, the value is 1.38. This value is below the healthy minimum of 10. It has decreased from 1.65 (Mar 24) to 1.38, marking a decrease of 0.27.
- For Return On Assets (%), as of Mar 25, the value is -43.67. This value is below the healthy minimum of 5. It has decreased from -43.18 (Mar 24) to -43.67, marking a decrease of 0.49.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 0.2. It has decreased from -0.08 (Mar 24) to -0.09, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is -1.03. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded -1.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Current Ratio (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 1.5. There is no change compared to the previous period (Mar 24) which recorded 0.04.
- For Quick Ratio (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.04.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -1.62. This value is below the healthy minimum of 3. It has increased from -3.56 (Mar 24) to -1.62, marking an increase of 1.94.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -1.62. This value is below the healthy minimum of 3. It has increased from -3.56 (Mar 24) to -1.62, marking an increase of 1.94.
- For Enterprise Value (Cr.), as of Mar 25, the value is 90.61. It has increased from 75.80 (Mar 24) to 90.61, marking an increase of 14.81.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / EBITDA (X), as of Mar 25, the value is -201.50. This value is below the healthy minimum of 5. It has decreased from -142.51 (Mar 24) to -201.50, marking a decrease of 58.99.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is -1.50. This value is below the healthy minimum of 1. It has decreased from -1.12 (Mar 24) to -1.50, marking a decrease of 0.38.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded -0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gayatri BioOrganics Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 1.38% (Industry Average ROCE: 40.7%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 0%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -1.62
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.04
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 0)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -1.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Organic - Cellulose Derivatives | B3, 3rd Floor, 6-3-1090, Rajbhavan Road, Hyderabad Telangana 500082 | info@gayatribioorganics.com http://www.gayatribioorganics.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. T V Sandeep Kumar Reddy | Chairman & Non-Exe.Director |
| Mr. K Sreedhara Reddy | Whole Time Director |
| Mrs. Meenakshi Ramchand Sachdeva | Independent Director |
| Mr. P V Narayana Rao | Independent Director |
| Mr. Srinivas Iduri | Independent Director |
FAQ
What is the intrinsic value of Gayatri BioOrganics Ltd?
Gayatri BioOrganics Ltd's intrinsic value (as of 15 December 2025) is 8.48 which is 44.94% lower the current market price of 15.40, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 122 Cr. market cap, FY2025-2026 high/low of 15.7/5.35, reserves of ₹-115.16 Cr, and liabilities of 1.67 Cr.
What is the Market Cap of Gayatri BioOrganics Ltd?
The Market Cap of Gayatri BioOrganics Ltd is 122 Cr..
What is the current Stock Price of Gayatri BioOrganics Ltd as on 15 December 2025?
The current stock price of Gayatri BioOrganics Ltd as on 15 December 2025 is 15.4.
What is the High / Low of Gayatri BioOrganics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gayatri BioOrganics Ltd stocks is 15.7/5.35.
What is the Stock P/E of Gayatri BioOrganics Ltd?
The Stock P/E of Gayatri BioOrganics Ltd is .
What is the Book Value of Gayatri BioOrganics Ltd?
The Book Value of Gayatri BioOrganics Ltd is 4.62.
What is the Dividend Yield of Gayatri BioOrganics Ltd?
The Dividend Yield of Gayatri BioOrganics Ltd is 0.00 %.
What is the ROCE of Gayatri BioOrganics Ltd?
The ROCE of Gayatri BioOrganics Ltd is 40.7 %.
What is the ROE of Gayatri BioOrganics Ltd?
The ROE of Gayatri BioOrganics Ltd is %.
What is the Face Value of Gayatri BioOrganics Ltd?
The Face Value of Gayatri BioOrganics Ltd is 10.0.